Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma

BACKGROUND: Neuroblastoma (NB) is the most frequent extracranial solid tumor in children. More than 50% of patients present with widespread (stage M) or refractory disease. In these patients, event-free and overall survival was improved by the addition of the anti-disialoganglioside antibody dinutux...

Descripción completa

Detalles Bibliográficos
Autores principales: Ehlert, Karoline, Hansjuergens, Ina, Zinke, Andreas, Otto, Sylke, Siebert, Nikolai, Henze, Guenter, Lode, Holger
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239695/
https://www.ncbi.nlm.nih.gov/pubmed/32414861
http://dx.doi.org/10.1136/jitc-2020-000540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7239695/
https://www.ncbi.nlm.nih.gov/pubmed/32414861
http://dx.doi.org/10.1136/jitc-2020-000540

Ejemplares similares